The role of cyclins in the development and progression of prostate cancer

Dulińska-Litewka, Joanna; Felkle, Dominik; Dykas, Kacper; Handziuk, Zuzanna; Krzysztofik, Marta; Gąsiorkiewicz, Bartosz

doi:10.1016/j.biopha.2022.113742

Cited by 6 publications

(1 citation statement)

References 139 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cell Cycle Staining Kit (CCS102, MULTI SCIENCES) was used for cell cycle analysis and the Annexin V-FITC/PI Cell Apoptosis Kit (AP101-100-kit, MULTI AGING SCIENCES) was used for apoptosis assays. The gene list of cyclins, cyclin-dependent kinases (CDKs), and cyclin-dependent kinase inhibitors (CDKIs) is referenced from previous studies [31][32][33].…”

Section: Cell Cycle Analysis and Cell Apoptosis Assaysmentioning

confidence: 99%

SPC25 as a novel therapeutic and prognostic biomarker and its association with glycolysis, ferroptosis and ceRNA in lung adenocarcinoma

Liu,

Zhang,

Ming

et al. 2024

Aging

View full text Add to dashboard Cite

Objective: Spindle pole body component 25 (SPC25) is an important cyclin involved in chromosome segregation and spindle dynamics regulation during mitosis. However, the role of SPC25 in lung adenocarcinoma (LAUD) is unclear. Materials and Methods: The differential expression of SPC25 in tumor samples and normal samples was analyzed using TIMER, TCGA, GEO databases, and the correlation between its expression and clinicopathological features and prognosis in LUAD patients. Biological pathways that may be enriched by SPC25 were analyzed using GSEA. In vitro cell experiments were used to evaluate the effect of knocking down SPC25 expression on LUAD cells. Correlation analysis and differential analysis were used to assess the association of SPC25 expression with genes related to cell cycle, glycolysis, and ferroptosis. A ceRNA network involving SPC25 was constructed using multiple database analyses. Results: SPC25 was highly expressed in LUAD, and its expression level could guide staging and predict prognosis. GSEA found that high expression of SPC25 involved multiple cell cycles and glycolytic pathways. Knocking down SPC25 expression significantly affected the proliferation, migration and apoptosis of LUAD cells. Abnormal SPC25 expression levels can affect cell cycle progression, glycolytic ability and ferroptosis regulation.A ceRNA network containing SPC25, SNHG15/hsa-miR-451a/SPC25, was successfully predicted and constructed. Conclusions: Our findings reveal the association of up-regulation of SPC25 in LUAD and its expression with clinical features, prognosis prediction, proliferation migration, cell cycle, glycolysis, ferroptosis, and ceRNA networks. Our results indicate that SPC25 can be used as a biomarker in LUAD therapy and a target for therapeutic intervention.

show abstract

Section: Cell Cycle Analysis and Cell Apoptosis Assaysmentioning

confidence: 99%